These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. In vitro effects of sulfacetamide on ocular strains of bacteria. LEIBOLD AM; SUIE T Am J Ophthalmol; 1958 Mar; 45(3):383-6. PubMed ID: 13508811 [No Abstract] [Full Text] [Related]
43. Inhibition of Methionine Synthesis in Escherichia coli by 2-Chloro-4-Aminobenzoic Acid and Sulfanilamide. Strandskov FB J Bacteriol; 1947 May; 53(5):555-9. PubMed ID: 16561307 [No Abstract] [Full Text] [Related]
44. Potentiation of sulphonamides. O'MEARA RA Lancet; 1952 Jan; 1(6698):107-8. PubMed ID: 14889776 [No Abstract] [Full Text] [Related]
45. The inhibition by p-aminobenzoic acid of the development of paludrine-resistance as produced by sulphonamides in Plasmodium gallinaceum. BISHOP A; McCONNACHIE EW Parasitology; 1951 Jul; 41(1-2):105-9. PubMed ID: 14863951 [No Abstract] [Full Text] [Related]
46. An amine ed formed by bacteria during sulfonamide bacteriostasis. STETTEN MR; FOX CL J Biol Chem; 1945; 161():333-49. PubMed ID: 21005740 [No Abstract] [Full Text] [Related]
47. [Antibacterial effect and resorption of a sulfanilamide-penicillin combination (elkocillin)]. ALLEMANN O Praxis; 1953 Mar; 42(12):229-33. PubMed ID: 13073788 [No Abstract] [Full Text] [Related]
48. Structure and activity of sulfanilamides. BORDWELL FG; COLBERT AB; ALAN B J Am Chem Soc; 1946 Sep; 68(9):1778-81. PubMed ID: 21001092 [No Abstract] [Full Text] [Related]
49. Antibacterial action of an oxidation product of sulfanilamide. BARKAN G; GOLDSMITH L J Am Chem Soc; 1946 May; 68():733. PubMed ID: 21024868 [No Abstract] [Full Text] [Related]
50. Transient myopia following the administration of sulphonamides. GRANSTROM KO Acta Ophthalmol (Copenh); 1949; 27(1):59-68. PubMed ID: 18144632 [No Abstract] [Full Text] [Related]
51. Transient myopia following the use of sulphonamides. MATTSSON R Acta Ophthalmol (Copenh); 1952; 30(4):385-98. PubMed ID: 13007446 [No Abstract] [Full Text] [Related]
52. How sulphonamides act. FRANK BL Lancet; 1948 Feb; 1(6496):345. PubMed ID: 18905402 [No Abstract] [Full Text] [Related]
53. Biochemical significance of the competition between p-aminobenzoic acid and the sulphonamides. WOODS DD Ann N Y Acad Sci; 1950 Jul; 52(8):1199-1211. PubMed ID: 15433142 [No Abstract] [Full Text] [Related]
54. Identification of sulphonamides on paper chromatograms. STEEL AE Nature; 1951 Nov; 168(4281):877. PubMed ID: 14899510 [No Abstract] [Full Text] [Related]
55. Choice of sulphonamides for mixture therapy. LEHR D Br Med J; 1950 Sep; 2(4679):601-4. PubMed ID: 14772424 [No Abstract] [Full Text] [Related]
56. The identification of the clinically-important sulphonamides. HUCKNALL E; TURFITT GE J Pharm Pharmacol; 1949 Jun; 1(6):368-76. PubMed ID: 18151718 [No Abstract] [Full Text] [Related]
57. Minimum rates of flow in therapy with sulphonamides. NELSON E Nature; 1961 Mar; 189():928-9. PubMed ID: 13728277 [No Abstract] [Full Text] [Related]
58. [Experimental evaluation of new sulfanilamides as preparation for clinical testing]. KRUEGER-THIEMER E Klin Wochenschr; 1962 Feb; 40():153-8. PubMed ID: 14459895 [No Abstract] [Full Text] [Related]
59. Hypoglycaemic and anti-diabetic sulphonamides. YOUNG FG Br Med J; 1956 Aug; 2(4990):431-2. PubMed ID: 13342506 [No Abstract] [Full Text] [Related]